Laurel A. Menapace

Lead Global Safety Officer, Rare Blood Disorders
Sanofi, Cambridge, MA, United States
Cambridge, Massachusetts, United States

Presentation(s):

• OC 14.2 - Surgical experience in people with hemophilia A or B with and without inhibitors receiving fitusiran

  Sunday, June 23, 2024
  09:45 – 10:00 ICT

• OC 40.2 - Incidence of thrombotic events in the fitusiran clinical development program

  Monday, June 24, 2024
  15:00 – 15:15 ICT

• OC 40.3 - Hepatobiliary events in the fitusiran clinical development program with the revised AT-based dose regimen

  Monday, June 24, 2024
  15:15 – 15:30 ICT